Decision-Based Paths Sample Clauses

Decision-Based Paths. ‌‌ In this section, I focus on different decisions an entrepreneur makes during the development of a start-up firm. A very early decision focuses on the industry segment for the entrepreneurial firm. The choice of industry can have a significant impact on the growth path of a technology-based new venture. A segment that is different when compared with other technology industries is biotechnology. As opposed to software, hardware, and service firms, life science ventures do not push customer-linking skills in the beginning. Biotech companies cannot approach the market with a new product and immediately start to market it. Instead they have to pass many different preclinical and clinical tests until they get the approval from a government agency to actually launch their drugs on the market (Kellogg and Xxxxxxx 2000). For the first phases, the failure rates are usually very high (Jägle 1999). In addition, the process requires substantial financial investments and long periods of time without generating any revenues (Shan, Walker, and Xxxxx 1994). While biotech companies are purely focused on the development of particular drugs, entrepreneurial firms in other industries have to develop market sensing and customer linking capabilities in order to attract and retain customers. Therefore, they invest in learning efforts in the fields of marketing and sales. When biotech companies finally get their products approved, they do not invest in production facilities and sell their drugs to patients. This is because large-scale production facilities in the health care sector require substantial investments. Instead, successful biotechnology ventures license their drugs to large incumbents who possess the financial resources to produce at high volume. Marketing and selling the products is often handled through partnerships. Although licensing deals may generate substantial revenues for the entrepreneurial firm, they are usually not realised by sales employees. In most cases, members of the top management team work on these deals. Thus, biotech ventures do not need to develop marketing and sales capabilities, which is expressed in the next hypothesis.
AutoNDA by SimpleDocs

Related to Decision-Based Paths

  • Additional RO Review Criteria (1) In addition to the requirements in Subparagraph 34A, the RO must:

  • Claims Review Methodology a. C laims Review Population. A description of the Population subject to the Quarterly Claims Review.‌

  • Claims Review Findings a. Narrative Results.‌‌

  • Decision and Appeal Within five school business days after receiving the Complaint Manager’s report, the Superintendent shall mail his or her written decision to the Complainant and the accused by first class U.S. mail as well as to the Complaint Manager. All decisions shall be based upon the preponderance of evidence standard. Within 10 school business days after receiving the Superintendent’s decision, the Complainant or the accused may appeal the decision to the Board by making a written request to the Complaint Manager. The Complaint Manager shall promptly forward all materials relative to the complaint and appeal to the Board. Within 30 school business days, the Board shall affirm, reverse, or amend the Superintendent’s decision or direct the Superintendent to gather additional information. Within five school business days after the Board’s decision, the Superintendent shall inform the Complainant and the accused of the Board’s action. For complaints containing allegations involving the Superintendent or Board member(s), within 30 school business days after receiving the Complaint Manager’s or outside investigator’s report, the Board shall mail its written decision to the Complainant and the accused by first class U.S. mail as well as to the Complaint Manager. This policy shall not be construed to create an independent right to a hearing before the Superintendent or Board. The failure to strictly follow the timelines in this grievance procedure shall not prejudice any party.

  • Grievance and Appeals Unit See Section 9 for contact information. You may also contact the Office of the Health Insurance Commissioner’s Consumer Resource Program, RIREACH at 1-855-747-3224 about questions or concerns you may have. Complaints A complaint is an expression of dissatisfaction with any aspect of our operation or the quality of care you received from a healthcare provider. A complaint is not an appeal. For information about submitting an appeal, please see the Reconsiderations and Appeals section below. We encourage you to discuss any concerns or issues you may have about any aspect of your medical treatment with the healthcare provider that furnished the care. In most cases, issues can be more easily resolved if they are raised when they occur. However, if you remain dissatisfied or prefer not to take up the issue with your provider, you can call our Customer Service Department for further assistance. You may also call our Customer Service Department if you are dissatisfied with any aspect of our operation. If the concern or issue is not resolved to your satisfaction, you may file a verbal or written complaint with our Grievance and Appeals Unit. We will acknowledge receipt of your complaint or administrative appeal within ten (10) business days. The Grievance and Appeals Unit will conduct a thorough review of your complaint and respond within thirty (30) calendar days of the date it was received. The determination letter will provide you with the rationale for our response as well as information on any possible next steps available to you. When filing a complaint, please provide the following information: • your name, address, member ID number; • the date of the incident or service; • summary of the issue; • any previous contact with BCBSRI concerning the issue; • a brief description of the relief or solution you are seeking; and • additional information such as referral forms, claims, or any other documentation that you would like us to review. Please send all information to the address listed on the Contact Information section.

  • Review Protocol A narrative description of how the Claims Review was conducted and what was evaluated.

  • Claims Review Population A description of the Population subject to the Claims Review.

  • How to File an Appeal of a Prescription Drug Denial For denials of a prescription drug claim based on our determination that the service was not medically necessary or appropriate, or that the service was experimental or investigational, you may request an appeal without first submitting a request for reconsideration. You or your physician may file a written or verbal prescription drug appeal with our pharmacy benefits manager (PBM). The prescription drug appeal must be submitted to us within one hundred and eighty (180) calendar days of the initial determination letter. You will receive written notification of our determination within thirty (30) calendar days from the receipt of your appeal. How to File an Expedited Appeal Your appeal may require immediate action if a delay in treatment could seriously jeopardize your health or your ability to regain maximum function, or would cause you severe pain. To request an expedited appeal of a denial related to services that have not yet been rendered (a preauthorization review) or for on-going services (a concurrent review), you or your healthcare provider should call: • our Grievance and Appeals Unit; or • our pharmacy benefits manager for a prescription drug appeal. Please see Section 9 for contact information. You will be notified of our decision no later than seventy-two (72) hours after our receipt of the request. You may not request an expedited review of covered healthcare services already received.

  • Committee Composition and Selection 1. The committee shall be comprised of eight members as follows: • five Teachers • three administrators

  • Review and Appeal (a) Each Party shall establish or maintain judicial, quasi-judicial, or administrative tribunals or procedures for the purpose of the prompt review and, where warranted, correction of final administrative actions regarding matters covered by this Treaty. Such tribunals shall be impartial and independent of the office or authority entrusted with administrative enforcement and shall not have any substantial interest in the outcome of the matter.

Time is Money Join Law Insider Premium to draft better contracts faster.